Quantcast
Home > Quotes > BLCM

Bellicum Pharmaceuticals, Inc. Common Stock (BLCM) Quote & Summary Data

BLCM 
$3.67
*  
0.08
2.23%
Get BLCM Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading BLCM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 3.71 / $ 3.50
Share Volume
556,755
50 Day Avg. Daily Volume
426,671
Previous Close
$ 3.59
52 Week High / Low
$ 10.26 / $ 3.59
Market Cap
159,135,454
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
556,755
50 Day Avg. Daily Volume:
426,671

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.49

Trading Range

The current last sale of $3.67 is 2.23% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.71 $ 10.26
 Low: $ 3.50 $ 3.59

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. We are using our proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer our product candidates with switch technologies that are designed to control components of the immune system in real time. By incorporating our CID platform, our product candidates may offer better safety and efficacy outcomes than are seen with current cellular immunotherapies. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including chimeric antigen receptor T cell therapy, or CAR T, T cell receptors, or TCRs and hematopoietic stem cell transplantation, or HSCT.  ... More ...  


Risk Grade

Where does BLCM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.61
Open Date:
Dec. 14, 2018
Close Price:
$ 3.67
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info